- Products in JAPAN
- A-Z List of Our Products /
Kusuri-no-Shiori® - Value-Added Products /
Advanced Generics(to be annouced) - Products in ASIA
- Hong Kong
- Malaysia(to be annouced)
- Thailand(to be annouced)
- May 14, 2018
- Year Ended March 31, 2018 Results Settlement of Accounts Supplementary Material (Apr.1 2017 to Mar.31 2018)
- May 14, 2018
- FY2017, ended March 2018, Presentation
- April 17, 2018
- Announcement of completion of new production facility by Aprogen Biologics Inc.
- March 29, 2018
- Strategic Alliance Agreement for the Generic Business of Nichi-Iko Pharmaceutical Co., Ltd. and Eisai Co., Ltd.
- March 28, 2018
- EISAI AND NICHI-IKO PHARMACEUTICAL ENTER INTO STRATEGIC ALLIANCE AGREEMENT
- February 22, 2018
- Consolidated Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31, 2018
- February 7, 2018
- Year Ending March 31, 2018 Results of 3rd Quarter Settlement of Accounts Supplementary Material (Apr.1 to Dec.31 2017)
- September 27, 2017
- Year Ending March 31, 2018 Results of 2nd Quarter Settlement of Accounts Supplementary Material (Apr.1 to Sep.30 2017)
- September 27, 2017
- About Joint Promotion of Infliximab BS for I.V.Infusion 100mg "Nichi-Iko"
- September 27, 2017
- About Marketing Approval for Infliximab BS for I.V.Infusion 100mg "AYUMI"
- September 27, 2017
- About Marketing Approval for Infliximab BS for I.V.Infusion 100mg "Nichi-Iko" and the Status of Development in the U.S.A.
- September 8, 2017
- Consolidated Financial Results for the 1st Quarter of the Fiscal Year Ending March 31, 2018
- August 9, 2017
- Year Ending March 31, 2018 Results of 1st Quarter Settlement of Accounts Supplementary Material (Apr.1 to Jun.30 2017)
- July 14, 2017
- Licensing Agreement for Marketing Rights to Infliximab BS for I.V.Infusion 100mg "AYUMI"
- June 19, 2017
- Consolidated Financial Results for the Fiscal Year Ended March 31, 2017
- May 30, 2017
- Notice of the 53nd Ordinary General Meeting of Shareholders
- May 10, 2017
- Consolidated Financial Results for the Fiscal Year Ended March 31, 2017 Results Settlement of Accounts Supplementary Material (Apr.1 2016 to Mar.31 2017)
- February 28, 2017
- Consolidated Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31, 2017
- February 8, 2017
- Year Ending March 31, 2017 Results of 3rd Quarter Settlement of Accounts Supplementary Material (Apr.1 to Dec.31 2016)
- December 1, 2016
- Consolidated Financial Results for the 2nd Quarter of the Fiscal Year Ending March 31, 2017
- November 7, 2016
- Year Ending March 31, 2017 Results of 2nd Quarter Settlement of Accounts Supplementary Material (Apr.1 to Sep.30 2016)
- August 31, 2016
- Consolidated Financial Results for the 1st Quarter of the Fiscal Year Ending March 31, 2017
- August 08, 2016
- Year Ending March 31, 2017 Results of 1st Quarter Settlement of Accounts Supplementary Material (Apr.1 to Jun.30 2016)
- June 13, 2016
- Consolidated Financial Results for the Fiscal Year Ended March 31, 2016
- May 31, 2016
- Notice of the 52nd Ordinary General Meeting of Shareholders
- December 2, 2015
- Notice of Sale of Shares Held by Nichi-Iko Pharmaceutical Co., Ltd.,Termination of Capital Alliance and Continuation of Business Alliance
- November 5, 2014
- Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31,2015
- August 11, 2014
- Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31,2015
- June 20, 2014
- Notice Concerning Issuance of Long-term Stock Options for Stock-based Compensation
- June 20, 2014
- New Products Released in June 2014
- May 13, 2014
- Scheduled Dividends for the Fiscal Year Ending March 31, 2015
- May 12, 2014
- Revision of the 6th Mid-term Business Plan "Pyramid"
- May 12, 2014
- Year Ended March 31, 2014 Results of Full year Settlement of accounts supplementary material (Apr.1 2013 to Mar.31 2014)
- May 12, 2014
- Consolidated Financial Results for the Fiscal Year Ended March 31, 2014
- March 10, 2014
- Notice of Decision on Name of New Company for Business Succession of Fuji Plant between the Company and Astellas Pharma Group: Nichi-Iko Pharma Tech Co., Ltd.
- February 12, 2014
- Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2014
- February 12, 2014
- Notice of Establishment of Subsidiary in USA
- January 30, 2014
- Notice Concerning the Transfer of Nichi-Iko Pharmaceutical Co., Ltd. Stock Acquisition Rights No.5
- January 28, 2014
- Notice Concerning the Status of Exercise (Final Status of Exercise by General Investors) and the Acquisition of Nichi-Iko Pharmaceutical Co., Ltd. Stock Acquisition Rights No.5
- January 24, 2014
- Notice Concerning the Status of Exercise of Nichi-Iko Pharmaceutical Co., Ltd. Stock Acquisition Rights No.5 (As of January 22, 2014) and the Total Number of Issued Shares (As of January 23, 2014)
- January 24, 2014
- Notice of Establishment of Local Corporation in Thailand
- January 22, 2014
- Notice Concerning the Status of Exercise of Nichi-Iko Pharmaceutical Co., Ltd. Stock Acquisition Rights No.5 (As of January 20, 2014) and the Total Number of Issued Shares (As of January 21, 2014)
- January 20, 2014
- Notice Concerning the Status of Exercise of Nichi-Iko Pharmaceutical Co., Ltd. Stock Acquisition Rights No.5 (As of January 16, 2014) and the Total Number of Issued Shares (As of January 17, 2014)
- January 16, 2014
- Notice Concerning the Status of Exercise of Nichi-Iko Pharmaceutical Co., Ltd. Stock Acquisition Rights No.5 (As of January 14, 2014) and the Total Number of Issued Shares (As of January 15, 2014)
- January 16, 2014
- Notice Concerning Transfer of Major Shareholder
- January 14, 2014
- Notice Concerning the Status of Exercise of Nichi-Iko Pharmaceutical Co.,Ltd. Stock Acquisition Rights No.5 by Existing Shareholders, etc.
- December 13, 2013
- Notice of Final Agreement between the Company and Astellas Pharma Group for Business Acquisition of Fuji Plant
- December 3, 2013
- Notice Concerning Adjustment of Exercise Price of Existing Stock Option (Stock Acquisition Rights) of Nichi-Iko Pharmaceutical Co., Ltd.
- December 2, 2013
- Notice Concerning the Listing Date of Stock Acquisition Rights No.5 of Nichi-Iko Pharmaceutical Co., Ltd. Issued Through a Commitment-type Rights Offering
- November 27, 2013
- Notice Concerning the Commitment-type Rights Offering (Allotment of Listing-type Stock Acquisition Rights without Contribution)
Stock Acquisition Rights Exercise/Cancellation Request Form 114 KB
- November 27, 2013
- Explanation Concerning the Commitment-type Rights Offering (Allotment of Listing-type Stock Acquisition Rights without Contribution) (Q&A)
- November 27, 2013
- Notice Concerning Revision to Year-end Dividend Forecast
- November 27, 2013
- Investor Letter
- November 27, 2013
- Terms and Conditions of Allotment of the Stock Acquisition Rights No.5
- November 6, 2013
- Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31,2014
- October 2, 2013
- Statement of Agreement for Capital Alliance with Binex in Korea
- September 30, 2013
- Notice Concerning Determination of Terms of Issuance of Stock Options (Stock Acquisition Rights)
- September 27, 2013
- Notice of Basic Agreement for Business Acquisition of Fuji Plant of Astellas Pharma Group
- September 9, 2013
- Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)
- September 9, 2013
- Business Alliance with Biolab in Thailand
- August 9, 2013
- Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31,2014
- July 19, 2013
- Notice Concerning Determination of Terms of Issuance of Long-term Stock Options for Stock-based Compensation
- June 21, 2013
- Notice of the Resolutions at the 49th Annual General Meeting of Shareholders
- June 21, 2013
- Notice Concerning Issuance of Long-term Stock Options for Stock-based Compensation
- June 3, 2013
- Notice Concerning Issuance of Short-term and Mid-term Stock Options for Stock-based Compensation
- May 14, 2013
- Policy of Countermeasures against Large-Scale Acquisitions of Share Certificates, etc. of Nichi-Iko Pharmaceutical Co.,Ltd.(Takeover Defense Measures)
- May 14, 2013
- Notice Concerning Stock Options (Stock Acquisition Rights)
- May 14, 2013
- Notice Concerning Issuance of Short-term and Mid-term Stock Options for Stock-based Compensation
- May 14, 2013
- Consolidated Financial Results for the Fiscal Year Ended March 31,2013
- March 22, 2013
- Merger and Acquisition of Yakuhan Pharmaceutical Co., Ltd.
- March 1, 2013
- Completion of the Pyramid Building
- February 12, 2013
- Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2013
- February 12, 2013
- Establishment of Representative Office in Bangkok, Thailand
- December 12, 2012
- Nichi-Iko Ladies Open Golf Tournament
- November 13, 2012
- Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2013
- August 9, 2012
- Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2013
- November 24, 2011
- Listing on the First Section of the Tokyo Stock Exchange
- October 28, 2011
- Completion of Honeycomb Building, the Global Development and Quality Control Center
- October 21, 2010
- Capital and Business Alliance on R&D for Biosimilars
- July 28, 2010
- Agreement on Exclusive Representation with DKSH Group (Thailand, Malaysia, Hong Kong)
- May 28, 2010
- Agreement on a Strategic Partnership with Sanofi-Aventis(currently SANOFI) for Generic Pharmaceuticals in Japan
